Morgan Stanley
MENS

Morgan Stanley’s Jyong Biotech MENS Stock Holding History

Morgan Stanley’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7K Sell
6,112
-189
-3% -$401 ﹤0.01% 6971
2026
Q1 		$13.5K Sell
6,301
-21,812
-78% -$53.4K ﹤0.01% 6856
2025
Q4 		$111K Buy
28,113
+25,242
+879% +$891K ﹤0.01% 6146
2025
Q3 		$113K Buy
+2,871
New +$103K ﹤0.01% 6098

Other funds holding MENS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's MENS Position: Q2 2026 in Review

Morgan Stanley reduced its Jyong Biotech (MENS) stake by 3% in Q2 2026, selling an estimated $401 and leaving 6,112 shares worth $12.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6971.

Morgan Stanley first reported a position in MENS in Q3 2025 and has held it in 4 quarters since. The position peaked at $113K in Q3 2025. 19 funds tracked by Wall St. Rank hold MENS as of Q2 2026.

  • Morgan Stanley held 6,112 shares of Jyong Biotech worth $12.7K as of Q2 2026.
  • Morgan Stanley sold 189 Jyong Biotech shares in Q2 2026, an estimated $401.
  • Jyong Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6971 holding.
  • Morgan Stanley first reported a position in Jyong Biotech in Q3 2025 and has held it in 4 quarters since.
  • Morgan Stanley's Jyong Biotech position peaked at $113K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Jyong Biotech as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.